RESEARCH TRIANGLE PARK – ViiV Healthcare, which has a large research and development operation in RTP, has filed for approval of an AIDS treatment that would help people infected with HIV who have developed a resistance or intolerance to other medications.
Called fostemsavir, ViiV says it is “being developed for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a suppressive regimen due to resistance, intolerance or safety considerations.”
“We’ve made incredible strides in our understanding and treatment of HIV over the past 30 years,” said Kimberly Smith, head of Research & Development at ViiV, in a statement.
ViiV Healthcare HIV treatment shows success in 2-month treatment trial
“However, the complexities of the virus mean that unsuccessful treatment and antiviral resistance are still major concerns for certain people living with HIV. Through our perseverance in research and development, these individuals may soon have an entirely new way to target and treat HIV with fostemsavir, aiding them in their efforts to achieve viral suppression.”
The drug has already received fast-track designation from the FDA.
ViiV focuses on HIV therapy.
GSK said regulatory approval in Europe also will be sought.
Read the full announcement online.
